$7.04
-0.17-2.36%
Last update: Dec 15, 3:41 PM
Myriad Genetics issues guidance on future EPS and revenue, giving investors insight into how much the company expects to earn in upcoming periods.
The most recent guidance for Myriad Genetics (MYGN) was reported on November 3, 2025 for the full year 2025. The company provided earnings per share guidance in the range of $-0.02 to $0.02, compared to the estimated EPS of $-0.16. Additionally, Myriad Genetics forecasted revenue between $0.82B and $0.83B for the quarter.
Browse guidance and forecast on all stocks.